Analysis of clinical and molecular biological characteristics of patients with acute myel-oid leukemia complicated with TP53gene mutations
10.12354/j.issn.1000-8179.2024.20240110
- VernacularTitle:TP53基因突变急性髓系白血病患者临床及分子生物学特征分析
- Author:
Xu LEI
1
;
Lin GUOQIANG
Author Information
1. 徐州医科大学附属淮安医院(淮安市第二人民医院)检验科(江苏省淮安市 223022)
- Keywords:
TP53;
gene mutation;
acute myeloid leukemia(AML);
karyotype;
prognosis
- From:
Chinese Journal of Clinical Oncology
2024;51(6):281-286
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical and molecular biological characteristics of patients with acute myeloid leukemia(AML)complic-ated with TP53mutations.Methods:We retrospectively analyzed the clinical data of 256 patients who were initially diagnosed with AML us-ing polymerase chain reaction(PCR)combined with gene sequencing technology at Huai'an Hospital Affiliated to Xuzhou Medical University from July 2017 to May 2023.The mutation detection rate of the TP53 gene was determined,and clinical,laboratory,molecular,karyotype,and overall survival of patients with TP53 gene mutations were analyzed.Results:The TP53 gene mutation detection rate was 7.8%.The TP53gene mutation and non-mutation groups differed significantly in age,WHO type,white blood cell(WBC)count,and origin of bone mar-row cells(P<0.05).However,the two groups did not significantly differ in the incidence rates of BCR-ABL,NPM1 mutation,CEBPA mutation,RUNX1-RUNX1T1,MLL-related fusion gene,FLT3-ITD mutation,and CBFβ-MYH11 mutation(P>0.05).The detection rates of the monomer karyotype,complex karyotype,and abnormal karyotypes-17/17p-,-7/7q-,and-3/3q-in the TP53 gene mutation group significantly differed from those in the TP53 gene non-mutation group(P<0.05).The TP53 gene non-mutation group had a significantly better total survival time than the TP53 gene mutation group(Log-rank χ2=3.867,P<0.05).The univariate and multivariate Cox regression analyses identified the WBC count and TP53 gene mutations as independent influencing factors for patients with AML(both P<0.05).Conclusions:Patients with AML car-rying TP53 gene mutations exhibit specific clinical and molecular biological characteristics and have a poor prognosis.
